Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial

BACKGROUND: Masitinib is a highly selective tyrosine kinase inhibitor with activity against the main oncogenic drivers of gastrointestinal stromal tumor (GIST). Masitinib was evaluated in patients with advanced GIST after imatinib failure or intolerance. PATIENTS AND METHODS: Prospective, multicente...

詳細記述

保存先:
書誌詳細
主要な著者: Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B. A., Bulusu, V. R., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., Le Cesne, A.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2014
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4143095/
https://ncbi.nlm.nih.gov/pubmed/25122671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu237
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料